Corcept Therapeutics Inc (CORT) Stock
Key stats
- Market cap
- $8.86B
- Price / Earnings ratio
- 160.5x
- EPS (TTM)
- $0.53
- Volume
- Loading
- 52-week high
- $126.38
- 52-week low
- $28.66
Source: third-party data provider, as of November 5, 2026
Compare with CORT
Recent news

Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics Q3 Earnings Call Highlights
CORT

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
CORT

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
CORT

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 23.83
- MACD 12/26/9
- -9.38
- EMA 9 of MACD
- -6.81
- MACD histogram
- -2.57
- SMA 50
- $109.43
- Price below SMA 50
- EMA 50
- $103.62
- Price below EMA 50
- SMA 200
- $75.45
- Price above SMA 200
- EMA 200
- $82.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.35 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics Q3 Earnings Call Highlights
CORT

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
CORT

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
CORT

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORT

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
CORT

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
CORT

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
CORT

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
CORT

3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
CORT

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
CORT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Corcept Therapeutics Inc
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 1957 |
| Mr. Atabak Mokari | CFO & Treasurer | 1977 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 1968 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 1963 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 1978 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 1960 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | — |
| Ms. Monica Tellado | President of Emerging Markets | 1973 |
| Mr. Roberto W. Vieira | President of Oncology | — |
| Mr. Justin Gunn M.D. | President of Endocrinology | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 5, 2026
Technical indicators
- RSI 14
- 23.83
- MACD 12/26/9
- -9.38
- EMA 9 of MACD
- -6.81
- MACD histogram
- -2.57
- SMA 50
- $109.43
- Price below SMA 50
- EMA 50
- $103.62
- Price below EMA 50
- SMA 200
- $75.45
- Price above SMA 200
- EMA 200
- $82.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $165.00
- Average
- $169.00
- High
- $173.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.5 | -6.4 | ||||||||||
| 2022 | -7.7 | +18.5 | -2.7 | -9.0 | -5.5 | +14.7 | +12.7 | -5.5 | -1.3 | +9.7 | -15.6 | -18.6 |
| 2023 | +13.3 | -13.0 | +9.1 | +0.1 | +3.2 | -3.1 | +15.2 | +30.9 | -17.7 | +6.8 | -9.3 | +25.1 |
| 2024 | -12.7 | +8.6 | +4.7 | -9.4 | +26.3 | +3.8 | +18.4 | -7.0 | +35.1 | +4.7 | +21.1 | -14.9 |
| 2025 | +33.9 | -9.0 | +93.4 | -21.8 | +8.5 | +2.4 | -3.1 | +1.0 | +16.4 | -12.8 | +7.1 | -56.4 |
| 2026 | +4.4 | -12.3 | +12.1 | +10.8 | +35.1 | +23.4 | +29.4 | +0.5 | +1.6 | -28.9 | +1.8 |



